Reproductive Endocrinology — MCQs

Reproductive Endocrinology Indian Medical PG Practice Questions and MCQs

Question 231: Menstruation is defined as precocious if it starts before the child reaches the age of:

A. 8 years
B. 10 years (Correct Answer)
C. 14 years
D. 20 years

Explanation: **Explanation:** The onset of puberty is a sequential process governed by the activation of the Hypothalamic-Pituitary-Ovarian (HPO) axis. In girls, the standard sequence is **Thelarche** (breast development), followed by **Pubarche/Adrenarche** (pubic/axillary hair), a **Peak Height Velocity** (growth spurt), and finally **Menarche** (onset of menstruation). **Why 10 years is the correct answer:** While **Precocious Puberty** is generally defined as the appearance of any secondary sexual characteristics before the age of **8 years** in girls, **Precocious Menarche** specifically refers to the onset of menstruation before the age of **10 years**. Menarche is typically the final milestone of puberty, occurring roughly 2–2.5 years after thelarche. If a girl menstruates before age 10, it is considered pathologically early and warrants investigation for causes such as McCune-Albright syndrome or hypothalamic lesions. **Analysis of Incorrect Options:** * **A. 8 years:** This is the cutoff for the onset of *any* secondary sexual characteristics (Thelarche). Menarche before 8 is extremely rare and always considered precocious, but the clinical definition for menarche specifically extends to age 10. * **C. 14 years:** This is related to the definition of **Primary Amenorrhea**. If a girl has no secondary sexual characteristics by age 13 or has not menstruated by age 15 (with secondary characteristics), it is considered delayed. * **D. 20 years:** This is well beyond the physiological range for pubertal onset and is clinically irrelevant to the definition of precocity. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of Precocious Puberty:** Idiopathic (80-90% of cases in girls). * **Sequence of Puberty:** T $\rightarrow$ P $\rightarrow$ H $\rightarrow$ M (Thelarche $\rightarrow$ Pubarche $\rightarrow$ Height spurt $\rightarrow$ Menarche). * **Bone Age:** In precocious puberty, bone age is typically advanced, leading to early epiphyseal closure and short adult stature. * **Drug of Choice:** GnRH agonists (e.g., Leuprolide) are used to "reset" the HPO axis in central precocious puberty.

Question 232: Which of the following statements regarding insulin resistance in women with PCOS is false?

A. Both lean and obese women with PCOS can exhibit insulin resistance.
B. Beta-cell dysfunction, independent of obesity, can be observed in PCOS.
C. Acanthosis nigricans and skin tags are dermatologic manifestations of insulin resistance.
D. Although insulin resistance is highly prevalent in PCOS, progression to type 2 diabetes is uncommon. (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is the correct (False) statement:** Polycystic Ovary Syndrome (PCOS) is a significant metabolic risk factor. Contrary to the statement, women with PCOS have a **3 to 5-fold increased risk** of progressing to Type 2 Diabetes Mellitus (T2DM). Approximately 10% of women with PCOS develop T2DM by age 40, and up to 30-35% exhibit Impaired Glucose Tolerance (IGT). The progression from IGT to T2DM is much more rapid in PCOS patients than in the general population, making regular screening (OGTT) essential. **2. Analysis of Incorrect Options (True Statements):** * **Option A:** While obesity exacerbates the condition, insulin resistance in PCOS is "intrinsic." It is mediated by post-receptor signaling defects (increased serine phosphorylation of the insulin receptor). Thus, even **lean women** with PCOS exhibit higher insulin resistance than weight-matched controls. * **Option B:** PCOS involves a dual defect: peripheral insulin resistance and **intrinsic beta-cell dysfunction**. The pancreas often fails to compensate for the insulin resistance, leading to early onset of glucose intolerance independent of BMI. * **Option C:** Hyperinsulinemia stimulates IGF-1 receptors in the skin, leading to epidermal hyperplasia. This manifests clinically as **Acanthosis Nigricans** (velvety hyperpigmentation) and **Acrochordons** (skin tags), which serve as reliable clinical markers for insulin resistance. **Clinical Pearls for NEET-PG:** * **Gold Standard for measuring IR:** Hyperinsulinemic-euglycemic clamp (rarely used clinically). * **Screening:** The 75g Oral Glucose Tolerance Test (OGTT) is superior to HbA1c for diagnosing IGT/T2DM in PCOS. * **First-line Management:** Weight loss and exercise are primary; Metformin is the insulin sensitizer of choice for metabolic derangements. * **HAIR-AN Syndrome:** Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans.

Question 233: Which of the following is true about Polycystic Ovarian Disease (PCOD)?

A. Hirsutism and hypertension
B. Oligomenorrhea and hypertension
C. Hirsutism, oligomenorrhea, and hypertension (Correct Answer)
D. Polymenorrhea

Explanation: **Explanation:** Polycystic Ovarian Disease (PCOD/PCOS) is a complex endocrine disorder characterized by the classic triad of **hyperandrogenism, ovulatory dysfunction, and metabolic disturbances.** **Why Option C is Correct:** 1. **Hirsutism:** This is the clinical manifestation of hyperandrogenism (excessive terminal hair growth in a male-pattern distribution). It is a hallmark feature of PCOD. 2. **Oligomenorrhea:** Chronic anovulation leads to infrequent menstrual cycles (oligomenorrhea) or total absence of periods (amenorrhea). 3. **Hypertension:** PCOD is strongly associated with **Metabolic Syndrome**. Insulin resistance leads to hyperinsulinemia, which increases sympathetic activity and sodium retention, frequently resulting in hypertension and an increased risk of cardiovascular disease. **Analysis of Incorrect Options:** * **Options A & B:** While these contain correct elements, they are incomplete. Option C represents the most comprehensive clinical picture of the systemic nature of the disease. * **Option D (Polymenorrhea):** This refers to frequent menstrual cycles (intervals <21 days). PCOD is characterized by delayed cycles (Oligomenorrhea) due to the lack of regular ovulation. **NEET-PG High-Yield Pearls:** * **Rotterdam Criteria:** Diagnosis requires 2 out of 3: (1) Clinical/biochemical hyperandrogenism, (2) Oligo/anovulation, (3) Polycystic ovaries on USG ("String of pearls" appearance). * **LH:FSH Ratio:** Classically elevated to **3:1**. * **Gold Standard for Insulin Resistance:** Hyperinsulinemic-euglycemic clamp (though rarely used clinically). * **Drug of Choice:** Combined Oral Contraceptive Pills (OCPs) for cycle regulation; Clomiphene Citrate or Letrozole (current DOC) for infertility; Metformin for insulin resistance.

Question 234: What are the typical hormonal level changes observed in Polycystic Ovarian Disease (PCOD)?

A. Luteinizing Hormone (LH) decreases
B. Luteinizing Hormone (LH) increases, Follicle-Stimulating Hormone (FSH) increases
C. Insulin decreases
D. Testosterone increases (Correct Answer)

Explanation: **Explanation:** In Polycystic Ovarian Disease (PCOD/PCOS), the primary endocrine hallmark is **hyperandrogenism**. The correct answer is **Testosterone increases** because the high levels of Luteinizing Hormone (LH) stimulate the ovarian **theca cells** to overproduce androgens (testosterone and androstenedione). This excess testosterone is responsible for clinical features like hirsutism, acne, and male-pattern alopecia. **Analysis of Options:** * **Option A & B (LH/FSH changes):** In PCOD, there is an **increase in LH** and a **decrease or normal level of FSH**. This leads to a characteristic **LH:FSH ratio of >2:1 or 3:1**. LH is elevated due to increased GnRH pulse frequency, while FSH is relatively low, preventing follicular maturation and leading to anovulation. * **Option C (Insulin):** PCOD is strongly associated with **Insulin Resistance**. Consequently, the body compensates by producing more insulin, leading to **Hyperinsulinemia** (not a decrease). High insulin further stimulates theca cells to produce more testosterone and inhibits Sex Hormone Binding Globulin (SHBG) production in the liver, increasing free testosterone levels. **NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Rotterdam Criteria (requires 2 out of 3: Oligo/anovulation, Hyperandrogenism, and Polycystic ovaries on USG). * **SHBG Levels:** Always **decreased** in PCOD, which increases the "Free Androgen Index." * **Estrogen Status:** There is a state of **chronic hyperestrogenism** (specifically Estrone, E1) due to peripheral conversion of androgens in adipose tissue. This increases the risk of endometrial hyperplasia/carcinoma. * **Metabolic Marker:** Acanthosis nigricans is a clinical sign of underlying insulin resistance.

Question 235: What is the typical Luteinizing Hormone (LH) to Follicle-Stimulating Hormone (FSH) ratio in women diagnosed with polycystic ovarian disease?

A. 1:02
B. 2:01 (Correct Answer)
C. 1:01
D. 3:01

Explanation: **Explanation:** In Polycystic Ovarian Syndrome (PCOS), the characteristic endocrine hallmark is an **elevation in the LH:FSH ratio**. This occurs due to an increased frequency and amplitude of Gonadotropin-Releasing Hormone (GnRH) pulses, which preferentially stimulates the anterior pituitary to secrete LH over FSH. 1. **Why 2:1 is correct:** While a ratio of **>2:1 or 3:1** is classically associated with PCOS, the most commonly tested threshold in medical examinations is **2:1**. High LH levels stimulate the ovarian theca cells to produce excess androgens (androstenedione and testosterone). Meanwhile, relatively low FSH levels result in poor follicular recruitment and a failure to convert these androgens into estrogens (via aromatase), leading to follicular atresia and the "necklace appearance" of cysts on ultrasound. 2. **Why other options are incorrect:** * **1:1:** This is the normal physiological ratio during the early follicular phase of a healthy menstrual cycle. * **1:2:** An inversion where FSH is higher than LH is typically seen in states of ovarian failure (Menopause) or Premature Ovarian Insufficiency. * **3:1:** While this ratio is highly suggestive of PCOS, **2:1** is the standard diagnostic benchmark used in most clinical textbooks and NEET-PG patterns. **High-Yield Clinical Pearls for NEET-PG:** * **Rotterdam Criteria:** Diagnosis requires 2 out of 3: (1) Oligo/Anovulation, (2) Hyperandrogenism (Clinical/Biochemical), (3) Polycystic ovaries on USG. * **Gold Standard:** The LH:FSH ratio is **no longer** a mandatory part of the Rotterdam criteria but remains a classic "textbook" biochemical marker. * **Insulin Resistance:** Hyperinsulinemia decreases Sex Hormone Binding Globulin (SHBG), further increasing free testosterone levels.

Question 236: A patient presents with amenorrhea and galactorrhea, and has elevated prolactin levels. She is not pregnant. In addition to evaluating for a prolactinoma, what other investigations can assess the cause of hyperprolactinemia?

A. Corticotropin-releasing hormone (CRH) stimulation test
B. Dopamine challenge test
C. Histamine type II receptor antagonist challenge
D. Thyrotropin-releasing hormone (TRH) stimulation test (Correct Answer)

Explanation: ### Explanation **Correct Option: D. Thyrotropin-releasing hormone (TRH) stimulation test** **Why it is correct:** The regulation of prolactin (PRL) is unique because it is primarily under **tonic inhibitory control** by dopamine. However, **Thyrotropin-releasing hormone (TRH)** acts as a potent prolactin-releasing factor. In patients with primary hypothyroidism, low levels of thyroxine (T4) lead to a compensatory increase in TRH. This elevated TRH stimulates lactotrophs in the anterior pituitary, causing **hyperprolactinemia**. Therefore, evaluating the thyroid axis is a crucial step in the workup of galactorrhea-amenorrhea syndrome. A TRH stimulation test can help differentiate between pituitary causes and thyroid-driven causes of elevated prolactin. **Why the other options are incorrect:** * **A. CRH stimulation test:** This is used to evaluate the hypothalamic-pituitary-adrenal (HPA) axis, specifically in the differential diagnosis of Cushing’s syndrome or adrenal insufficiency. It has no direct role in prolactin regulation. * **B. Dopamine challenge test:** While dopamine inhibits prolactin, a "challenge test" is not a standard clinical investigation for hyperprolactinemia. Instead, dopamine *agonists* (like Bromocriptine) are used for treatment. * **C. Histamine type II receptor antagonist challenge:** While certain H2 blockers (like Cimetidine) can cause hyperprolactinemia as a side effect, they are not used as a diagnostic investigation to assess the cause of the condition. **High-Yield Clinical Pearls for NEET-PG:** * **First step in evaluation:** Always rule out pregnancy (hCG test) and drug history (antipsychotics, metoclopramide). * **Hypothyroidism Link:** Primary hypothyroidism is a common, reversible cause of hyperprolactinemia. Always check **TSH levels**. * **Hook Effect:** In cases of giant adenomas with paradoxically low prolactin, serial dilutions of the serum are needed to overcome the "hook effect" in immunoassays. * **Treatment of choice:** Medical management with Dopamine agonists (**Cabergoline** is preferred over Bromocriptine due to higher efficacy and fewer side effects).

Question 237: Withdrawal bleeding occurs when progestin is administered continuously?

A. Estrogen concentration is sufficient (Correct Answer)
B. Structural abnormality in the pelvis
C. Associated with endocrine disorder
D. Atrophic endometrium

Explanation: ### Explanation The **Progesterone Challenge Test (PCT)** is a fundamental clinical tool used to assess the functional integrity of the hypothalamic-pituitary-ovarian (HPO) axis and the outflow tract in patients with secondary amenorrhea. **Why Option A is Correct:** For withdrawal bleeding to occur after progestin administration, two conditions must be met: 1. **Primed Endometrium:** The endometrium must have been previously exposed to sufficient levels of **estrogen** (endogenous) to undergo proliferation. Progesterone then converts this proliferative endometrium into a secretory one. When progesterone is withdrawn, the structural support of the endometrium collapses, leading to sloughing (bleeding). 2. **Patent Outflow Tract:** The uterus, cervix, and vagina must be patent. Therefore, a positive PCT (bleeding) confirms that the patient is **euestrogenic** and has a functional outflow tract. **Why Other Options are Incorrect:** * **B & C:** While endocrine disorders (like PCOS) or structural issues can cause amenorrhea, they do not *enable* withdrawal bleeding. In fact, structural abnormalities (like Asherman Syndrome) would result in a *negative* withdrawal test. * **D. Atrophic Endometrium:** An atrophic endometrium occurs in hypoestrogenic states (e.g., menopause or premature ovarian failure). Without estrogen to "prime" or thicken the lining, progesterone cannot cause it to shed, resulting in no bleeding. **High-Yield Clinical Pearls for NEET-PG:** * **Positive PCT:** Suggests **Anovulation** (e.g., PCOS). The body has estrogen but lacks progesterone due to the absence of a corpus luteum. * **Negative PCT:** Indicates either **Hypoestrogenism** (low FSH/LH or high FSH) or an **Outflow Tract Obstruction** (Asherman Syndrome/Cervical Stenosis). * **Next Step after Negative PCT:** Administer **Estrogen + Progesterone**. If bleeding occurs now, the outflow tract is intact, and the problem is lack of estrogen. If bleeding still does not occur, the diagnosis is an outflow tract abnormality.

Question 238: What is the typical hormonal status in Polycystic Ovarian Disease (PCOD)?

A. LH Increased, FSH Normal to Low (Correct Answer)
B. LH Decreased
C. FSH Increased
D. 17 OH Progesterone Normal

Explanation: **Explanation:** In Polycystic Ovarian Disease (PCOD/PCOS), the primary endocrine hallmark is a disruption of the hypothalamic-pituitary-ovarian axis. The correct answer is **A (LH Increased, FSH Normal to Low)**. **Why Option A is Correct:** In PCOS, there is an increase in the **GnRH pulse frequency**, which preferentially stimulates the anterior pituitary to secrete **Luteinizing Hormone (LH)**. High LH levels act on the ovarian theca cells to increase androgen production. Conversely, **Follicle Stimulating Hormone (FSH)** levels remain normal or low due to the negative feedback from high levels of estrone (converted from androgens in peripheral fat) and inhibin. This leads to the characteristic **LH:FSH ratio of >2:1 or 3:1**. **Why Other Options are Incorrect:** * **B (LH Decreased):** LH is characteristically elevated in PCOS, driving hyperandrogenism. * **C (FSH Increased):** FSH is typically low or at the lower end of the normal range. High FSH is seen in Premature Ovarian Failure (POF) or Menopause. * **D (17-OH Progesterone Normal):** While 17-OHP can be normal in PCOS, it is often **mildly elevated** (but <200 ng/dL). This option is less definitive than the LH/FSH imbalance which defines the core pathophysiology. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Diagnosis:** Rotterdam Criteria (requires 2 out of 3: Oligo/anovulation, Hyperandrogenism, and Polycystic ovaries on USG). * **The "String of Pearls" sign:** Seen on USG (12 or more follicles, 2-9 mm in diameter). * **Metabolic Link:** Hyperinsulinemia and Insulin Resistance are central to the pathogenesis, often leading to Acanthosis Nigricans. * **DOC for Ovulation Induction:** Letrozole (Aromatase inhibitor) is now preferred over Clomiphene Citrate.

Question 239: A tall adolescent presents with primary amenorrhea. On examination, she has normal breast development, absent axillary and pubic hair, and an inguinal hernia. What is the probable diagnosis?

A. Complete gonadal dysgenesis
B. Mayer-Rokitansky-Küster-Hauser syndrome
C. Androgen insensitivity syndrome (Correct Answer)
D. Congenital adrenal hyperplasia

Explanation: ### Explanation The clinical presentation points toward **Androgen Insensitivity Syndrome (AIS)**, specifically the complete form. **1. Why Androgen Insensitivity Syndrome (AIS) is correct:** AIS is an X-linked recessive condition where a genotypic male (46, XY) has a functional mutation in the androgen receptor. * **Breast development:** Occurs because the testes produce testosterone, which is peripherally converted to estrogen (aromatization). * **Absent hair:** Axillary and pubic hair growth is dependent on androgen action; since receptors are non-functional, hair is absent or sparse. * **Inguinal hernia:** This is a classic sign in AIS, representing the undescended testes (cryptorchidism) located in the inguinal canal. * **Tall stature:** Due to the presence of the Y chromosome and the lack of androgen-mediated epiphyseal closure. **2. Why other options are incorrect:** * **Complete Gonadal Dysgenesis (Swyer Syndrome):** These patients have a 46, XY karyotype but streak gonads. They lack estrogen, so they present with **no breast development** (sexual infantilism). * **MRKH Syndrome:** These are genotypic females (46, XX) with normal ovaries. They have **normal pubic and axillary hair** because their androgen receptors function normally. * **Congenital Adrenal Hyperplasia (CAH):** This typically presents with ambiguous genitalia and **virilization** (excess hair/clitoromegaly) in females, not normal breast development with absent hair. **3. NEET-PG High-Yield Pearls:** * **AIS vs. MRKH:** The most common "differentiating" factor in exams is **hair distribution** (Absent in AIS, Normal in MRKH) and **Karyotype** (46, XY in AIS, 46, XX in MRKH). * **Management of AIS:** Gonadectomy is performed **after puberty** to allow for natural breast development (via aromatization), followed by estrogen replacement to prevent osteoporosis. * **Vagina:** In both AIS and MRKH, the vagina is a short, blind-ended pouch.

Question 240: Which statement is true regarding Androgen Insensitivity Syndrome?

A. Phenotype may be completely female. (Correct Answer)
B. There is a predominant ovarian component in the gonads.
C. It always affects females.
D. Testes are formed abnormally and receptors are normal.

Explanation: **Explanation:** **Androgen Insensitivity Syndrome (AIS)**, formerly known as Testicular Feminization Syndrome, is an X-linked recessive condition where a mutation in the androgen receptor gene prevents target tissues from responding to testosterone. 1. **Why Option A is correct:** In **Complete AIS (CAIS)**, the body is entirely unresponsive to androgens. Despite having a 46,XY karyotype and functioning testes, the external genitalia develop along female lines due to the default pathway. At puberty, peripheral conversion of testosterone to estrogen leads to breast development (thelarche), resulting in a **completely female phenotype**, though they lack internal female pelvic organs. 2. **Why other options are incorrect:** * **Option B:** The gonads are **testes**, not ovaries. SRY gene expression on the Y chromosome ensures testicular development. * **Option C:** It affects **genotypic males (46,XY)**. While the phenotype is female, the genetic sex is male. * **Option D:** The **testes are formed normally** (producing normal/high levels of testosterone and Anti-Müllerian Hormone); the defect lies in the **androgen receptors**, which are either absent or non-functional. **High-Yield Clinical Pearls for NEET-PG:** * **Clinical Presentation:** Primary amenorrhea in a tall, well-developed female with scant/absent pubic and axillary hair (due to androgen resistance). * **Internal Anatomy:** Vagina is short/blind-ending. Uterus, fallopian tubes, and upper 1/3 of the vagina are **absent** due to normal AMH production by the testes. * **Management:** Gonadectomy is performed **after puberty** (to allow natural completion of growth and breast development) to prevent gonadoblastoma/dysgerminoma. * **Differential:** In **Müllerian Agenesis (MRKH)**, pubic hair is normal and ovaries are present (46,XX).

Practice by Chapter

Hypothalamic-Pituitary-Ovarian Axis

Practice Questions

Disorders of Puberty

Practice Questions

Hirsutism and Virilization

Practice Questions

Primary Ovarian Insufficiency

Practice Questions

Hyperprolactinemia

Practice Questions

Hyperandrogenism

Practice Questions

Metabolic Dysfunction in PCOS

Practice Questions

Neuroendocrine Disorders and Reproduction

Practice Questions

Hormonal Evaluation and Testing

Practice Questions

Ovulation Induction

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free